{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T02:02:20Z","timestamp":1784772140542,"version":"3.55.0"},"reference-count":139,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.semarthrit.2022.152062","type":"journal-article","created":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T04:09:03Z","timestamp":1656648543000},"page":"152062","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Immunopathogenesis of Sjogren's syndrome: Current state of DAMPs"],"prefix":"10.1016","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4861-4864","authenticated-orcid":false,"given":"Bingxia","family":"Ming","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaowu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jixin","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingli","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.semarthrit.2022.152062_bib0001","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMcp1702514","article-title":"Criswell primary Sjogren's syndrome","volume":"378","author":"Mariette","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2022.152062_bib0002","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1146\/annurev-pathol-012513-104728","article-title":"Moutsopoulos Sjogren's syndrome","volume":"9","author":"Mavragani","year":"2014","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.semarthrit.2022.152062_bib0003","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.clim.2017.03.007","article-title":"Tzioufas Insight into pathogenesis of Sjogren's syndrome: dissection on autoimmune infiltrates and epithelial cells","volume":"182","author":"Goules","year":"2017","journal-title":"Clin Immunol"},{"issue":"9","key":"10.1016\/j.semarthrit.2022.152062_bib0004","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1080\/1744666X.2019.1649596","article-title":"Predicting lymphoma development in patients with Sjogren's syndrome","volume":"15","author":"De Vita","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"issue":"7","key":"10.1016\/j.semarthrit.2022.152062_bib0005","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.autrev.2016.03.004","article-title":"Tzioufas Primary Sjgren's syndrome: clinical phenotypes, outcome and the development of biomarkers","volume":"15","author":"Goules","year":"2016","journal-title":"Autoimmun Rev"},{"issue":"11","key":"10.1016\/j.semarthrit.2022.152062_bib0006","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1136\/annrheumdis-2014-205375","article-title":"Epidemiology of primary Sjogren's syndrome: a systematic review and meta-analysis","volume":"74","author":"Qin","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152062_bib0007","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.autrev.2018.06.015","article-title":"Arthritis in primary Sjogren's syndrome: Characteristics, outcome and treatment from French multicenter retrospective study","volume":"18","author":"Mirouse","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152062_bib0008","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2019-216114","article-title":"EULAR recommendations for the management of Sjogren's syndrome with topical and systemic therapies","volume":"79","author":"Ramos-Casals","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"23","key":"10.1016\/j.semarthrit.2022.152062_bib0009","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21239172","article-title":"Makarenkova Innate Immunity and Biological Therapies for the Treatment of Sjogren's Syndrome","volume":"21","author":"Srivastava","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.152062_bib0010","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.autrev.2018.12.008","article-title":"The pipeline of targeted therapies under clinical development for primary Sjogren's syndrome: a systematic review of trials","volume":"18","author":"Felten","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.152062_bib0011","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1093\/rheumatology\/kez142","article-title":"Treatment of Sjogren's syndrome: current therapy and future directions","volume":"60","author":"Fox","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2022.152062_bib0012","article-title":"Correspondence on 'Interleukin 6 receptor inhibition in primary Sjogren syndrome: a multicentre double-blind randomised placebo-controlled trial","author":"Wang","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.152062_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102590","article-title":"Early diagnosis and treatment for Sjogren's syndrome: current challenges, redefined disease stages and future prospects","volume":"117","author":"Wang","year":"2021","journal-title":"J Autoimmun"},{"key":"10.1016\/j.semarthrit.2022.152062_bib0014","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1472-6831-13-51","article-title":"Temporal histological changes in lacrimal and major salivary glands in mouse models of Sjogren's syndrome","volume":"13","author":"Xuan","year":"2013","journal-title":"BMC Oral Health"},{"key":"10.1016\/j.semarthrit.2022.152062_bib0015","doi-asserted-by":"crossref","first-page":"w14168","DOI":"10.4414\/smw.2015.14168","article-title":"The value of histopathological examination of salivary gland biopsies in diagnosis, prognosis and treatment of Sjogren's Syndrome","volume":"145","author":"Barone","year":"2015","journal-title":"Swiss Med Wkly"},{"issue":"7","key":"10.1016\/j.semarthrit.2022.152062_bib0016","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1007\/s10067-018-4153-8","article-title":"Advances in the diagnosis and treatment of Sjogren's syndrome","volume":"37","author":"Chen","year":"2018","journal-title":"Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.152062_bib0017","first-page":"3","article-title":"One year in review 2020: pathogenesis of primary Sjogren's syndrome","volume":"38","author":"Bombardieri","year":"2020","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152062_bib0018","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1600-0714.2008.00700.x","article-title":"Activation of innate immune responses through Toll-like receptor 3 causes a rapid loss of salivary gland function","volume":"38","author":"Deshmukh","year":"2009","journal-title":"J Oral Pathol Med"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.152062_bib0019","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1365-2249.2006.03311.x","article-title":"Expression of functional Toll-like receptors by salivary gland epithelial cells: increased mRNA expression in cells derived from patients with primary Sjogren's syndrome","volume":"147","author":"Spachidou","year":"2007","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.semarthrit.2022.152062_bib0020","doi-asserted-by":"crossref","first-page":"16047","DOI":"10.1038\/nrdp.2016.47","article-title":"Casals Sjogren syndrome","volume":"2","author":"Brito-Zeron","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.semarthrit.2022.152062_bib0021","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.3389\/fimmu.2019.02536","article-title":"DAMPs and NETs in Sepsis","volume":"10","author":"Denning","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.semarthrit.2022.152062_bib0022","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1146\/annurev-pathmechdis-012419-032847","article-title":"Kubes DAMPs, PAMPs, and LAMPs in Immunity and Sterile Inflammation","volume":"15","author":"Zindel","year":"2020","journal-title":"Annu Rev Pathol"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.152062_bib0023","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8020201","article-title":"Obesity, inflammation, and prostate cancer","volume":"8","author":"Fujita","year":"2019","journal-title":"J Clin Med"},{"issue":"6002","key":"10.1016\/j.semarthrit.2022.152062_bib0024","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1126\/science.1195491","article-title":"Intravascular danger signals guide neutrophils to sites of sterile inflammation","volume":"330","author":"McDonald","year":"2010","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152062_bib0025","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1189\/jlb.0612293","article-title":"The dual roles of inflammatory cytokines and chemokines in the regulation of autoimmune diseases and their clinical implications","volume":"93","author":"Shachar","year":"2013","journal-title":"J Leukoc Biol"},{"issue":"9","key":"10.1016\/j.semarthrit.2022.152062_bib0026","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nri.2017.49","article-title":"Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy","volume":"17","author":"Nagarsheth","year":"2017","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.152062_bib0027","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.clinthera.2016.02.028","article-title":"Key role of DAMP in inflammation, cancer, and tissue repair","volume":"38","author":"Pandolfi","year":"2016","journal-title":"Clin Ther"},{"issue":"10","key":"10.1016\/j.semarthrit.2022.152062_bib0028","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.it.2007.08.004","article-title":"Lotze Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox","volume":"28","author":"Rubartelli","year":"2007","journal-title":"Trends Immunol"},{"issue":"11","key":"10.1016\/j.semarthrit.2022.152062_bib0029","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11882-018-0817-3","article-title":"Danger-associated molecular patterns (DAMPs): the derivatives and triggers of inflammation","volume":"18","author":"Patel","year":"2018","journal-title":"Curr Allergy Asthma Rep"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152062_bib0030","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/SHK.0b013e318277109c","article-title":"DAMPs, PAMPs, and the origins of SIRS in bacterial sepsis","volume":"39","author":"Gentile","year":"2013","journal-title":"Shock"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.152062_bib0031","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.cell.2010.01.022","article-title":"Pattern recognition receptors and inflammation","volume":"140","author":"Takeuchi","year":"2010","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.152062_bib0032","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/intimm\/dxp017","article-title":"The roles of TLRs, RLRs and NLRs in pathogen recognition","volume":"21","author":"Kawai","year":"2009","journal-title":"Int Immunol"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.152062_bib0033","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nri1372","article-title":"Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses","volume":"4","author":"Seong","year":"2004","journal-title":"Nat Rev Immunol"},{"issue":"14","key":"10.1016\/j.semarthrit.2022.152062_bib0034","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1111\/febs.13775","article-title":"Cell death and inflammation: the case for IL-1 family cytokines as the canonical DAMPs of the immune system","volume":"283","author":"Martin","year":"2016","journal-title":"FEBS J"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.152062_bib0035","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.molcel.2017.05.009","article-title":"Innate immune receptors as competitive determinants of cell fate","volume":"66","author":"Franz","year":"2017","journal-title":"Mol Cell"},{"key":"10.1016\/j.semarthrit.2022.152062_bib0036","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1146\/annurev-med-041316-085215","article-title":"Targeting RAGE signaling in inflammatory disease","volume":"69","author":"Hudson","year":"2018","journal-title":"Annu Rev Med"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152062_bib0037","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nri.2015.8","article-title":"Self-regulation and cross-regulation of pattern-recognition receptor signalling in health and disease","volume":"16","author":"Cao","year":"2016","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.152062_bib0038","doi-asserted-by":"crossref","first-page":"H184","DOI":"10.1152\/ajpheart.00328.2013","article-title":"Toll-like receptors and damage-associated molecular patterns: novel links between inflammation and hypertension","volume":"306","author":"McCarthy","year":"2014","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152062_bib0039","doi-asserted-by":"crossref","first-page":"72","DOI":"10.4049\/jimmunol.1601549","article-title":"Critical role of P2Y12 receptor in regulation of Th17 differentiation and experimental autoimmune encephalomyelitis pathogenesis","volume":"199","author":"Qin","year":"2017","journal-title":"J Immunol"},{"issue":"12","key":"10.1016\/j.semarthrit.2022.152062_bib0040","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/nri2873","article-title":"Sterile inflammation: sensing and reacting to damage","volume":"10","author":"Chen","year":"2010","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"10.1016\/j.semarthrit.2022.152062_bib0041","first-page":"1921","article-title":"Mice that exclusively express TLR4 on endothelial cells can efficiently clear a lethal systemic Gram-negative bacterial infection","volume":"119","author":"Andonegui","year":"2009","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152062_bib0042","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/JLB.4MIR1118-439R","article-title":"Visser Danger signals in oral cavity-related diseases","volume":"106","author":"Kay","year":"2019","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.semarthrit.2022.152062_bib0043","doi-asserted-by":"crossref","first-page":"578","DOI":"10.3389\/fpls.2014.00578","article-title":"Land danger signals - damaged-self recognition across the tree of life","volume":"5","author":"Heil","year":"2014","journal-title":"Front Plant Sci"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.152062_bib0044","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.4110\/in.2018.18.e27","article-title":"Damage-associated molecular patterns in inflammatory diseases","volume":"18","author":"Roh","year":"2018","journal-title":"Immune Netw"},{"key":"10.1016\/j.semarthrit.2022.152062_bib0045","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1146\/annurev.iy.12.040194.005015","article-title":"Tolerance, danger, and the extended family","volume":"12","author":"Matzinger","year":"1994","journal-title":"Annu Rev Immunol"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.152062_bib0046","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41577-019-0215-7","article-title":"DAMP-sensing receptors in sterile inflammation and inflammatory diseases","volume":"20","author":"Gong","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.152062_bib0047","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nrm2125","article-title":"Matrix metalloproteinases and the regulation of tissue remodelling","volume":"8","author":"Page-McCaw","year":"2007","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.semarthrit.2022.152062_bib0048","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.matbio.2015.02.003","article-title":"Proteoglycan form and function: a comprehensive nomenclature of proteoglycans","volume":"42","author":"Iozzo","year":"2015","journal-title":"Matrix Biol"},{"issue":"8","key":"10.1016\/j.semarthrit.2022.152062_bib0049","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1097\/IJG.0000000000000108","article-title":"Biology of the extracellular matrix: an overview","volume":"23","author":"Yue","year":"2014","journal-title":"J Glaucoma"},{"issue":"1-2","key":"10.1016\/j.semarthrit.2022.152062_bib0050","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.gene.2006.08.034","article-title":"The evolution of high mobility group box (HMGB) chromatin proteins in multicellular animals","volume":"387","author":"Sessa","year":"2007","journal-title":"Gene"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.152062_bib0051","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/1873-3468.12545","article-title":"The self-association of HMGB1 and its possible role in the binding to DNA and cell membrane receptors","volume":"591","author":"Anggayasti","year":"2017","journal-title":"FEBS Lett"},{"issue":"10","key":"10.1016\/j.semarthrit.2022.152062_bib0052","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1093\/rheumatology\/ket134","article-title":"The role of high mobility group box chromosomal protein 1 in rheumatoid arthritis","volume":"52","author":"Chen","year":"2013","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"10.1016\/j.semarthrit.2022.152062_bib0053","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1089\/ars.2013.5179","article-title":"Redox modulation of HMGB1-related signaling","volume":"20","author":"Janko","year":"2014","journal-title":"Antioxid Redox Signal"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.152062_bib0054","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1189\/jlb.1212662","article-title":"The many faces of HMGB1: molecular structure-functional activity in inflammation, apoptosis, and chemotaxis","volume":"93","author":"Yang","year":"2013","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.semarthrit.2022.152062_bib0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mam.2014.05.001","article-title":"HMGB1 in health and disease","volume":"40","author":"Kang","year":"2014","journal-title":"Mol Aspects Med"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.152062_bib0056","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1586\/1744666X.2014.909730","article-title":"Molecular mechanism and therapeutic modulation of high mobility group box 1 release and action: an updated review","volume":"10","author":"Lu","year":"2014","journal-title":"Expert Rev Clin Immunol"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.152062_bib0057","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/14728222.2018.1439924","article-title":"Extracellular HMGB1 as a therapeutic target in inflammatory diseases","volume":"22","author":"Andersson","year":"2018","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.semarthrit.2022.152062_bib0058","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.641973","article-title":"Extracellular HMGB1 contributes to the chronic cardiac allograft vasculopathy\/fibrosis by modulating TGF-beta1 signaling","volume":"12","author":"Zou","year":"2021","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.152062_bib0059","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.pharmthera.2013.11.001","article-title":"An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies","volume":"141","author":"Musumeci","year":"2014","journal-title":"Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.152062_bib0060","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3109\/03009742.2011.633099","article-title":"Increased serum levels of high-mobility group box 1 (HMGB1) in primary Sjogren's syndrome","volume":"41","author":"Dupire","year":"2012","journal-title":"Scand J Rheumatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.152062_bib0061","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1002\/acr.23420","article-title":"Association of high mobility group box chromosomal protein 1 and receptor for advanced glycation end products serum concentrations with extraglandular involvement and disease activity in Sjogren's syndrome","volume":"70","author":"Kanne","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"7","key":"10.1016\/j.semarthrit.2022.152062_bib0062","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1002\/art.21969","article-title":"Increased extracellular levels of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in minor salivary glands of patients with Sjogren's syndrome","volume":"54","author":"Ek","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.semarthrit.2022.152062_bib0063","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0183678","article-title":"Wee Effects of subconjunctival administration of anti-high mobility group box 1 on dry eye in a mouse model of Sjgren's syndrome","volume":"12","author":"Kim","year":"2017","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.152062_bib0064","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1139\/cjpp-2019-0337","article-title":"Suppression of high-mobility group box 1 ameliorates xerostomia in a Sjogren syndrome-triggered mouse model","volume":"98","author":"Wang","year":"2020","journal-title":"Can J Physiol Pharmacol"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152062_bib0065","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.immuni.2015.07.007","article-title":"Lambrecht barrier epithelial cells and the control of type 2 immunity","volume":"43","author":"Hammad","year":"2015","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.152062_bib0066","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.4049\/jimmunol.0802729","article-title":"The essential role of single Ig IL-1 receptor-related molecule\/Toll IL-1R8 in regulation of Th2 immune response","volume":"182","author":"Bulek","year":"2009","journal-title":"J Immunol"},{"issue":"23","key":"10.1016\/j.semarthrit.2022.152062_bib0067","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20235856","article-title":"IL-33\/IL-31 axis in immune-mediated and allergic diseases","volume":"20","author":"Murdaca","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.152062_bib0068","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102756","article-title":"Pathophysiologic role of Interleukin-33\/ST2 in Sjogren's syndrome","volume":"20","author":"Soyfoo","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2022.152062_bib0069","article-title":"Intratracheal Poly(I:C) exposure accelerates the immunological disorder of salivary glands in Sjogren's-like NOD\/ShiLtJ mice","volume":"8","author":"Hu","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.152062_bib0070","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.immuni.2015.02.011","article-title":"Cigarette smoke silences innate lymphoid cell function and facilitates an exacerbated type I interleukin-33-dependent response to infection","volume":"42","author":"Kearley","year":"2015","journal-title":"Immunity"},{"issue":"11","key":"10.1016\/j.semarthrit.2022.152062_bib0071","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nri.2016.95","article-title":"Interleukin-33 in health and disease","volume":"16","author":"Liew","year":"2016","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"10.1016\/j.semarthrit.2022.152062_bib0072","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1073\/pnas.1201042109","article-title":"Contribution of IL-33-activated type II innate lymphoid cells to pulmonary eosinophilia in intestinal nematode-infected mice","volume":"109","author":"Yasuda","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152062_bib0073","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cyto.2013.07.006","article-title":"Potential contribution of interleukin-33 to the development of interstitial lung disease in patients with primary Sjogren's Syndrome","volume":"64","author":"Zhao","year":"2013","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152062_bib0074","doi-asserted-by":"crossref","first-page":"39","DOI":"10.4103\/ijo.IJO_405_17","article-title":"Correlation of interleukin-33 with Th cytokines and clinical severity of dry eye disease","volume":"66","author":"Luo","year":"2018","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2022.152062_bib0075","doi-asserted-by":"crossref","first-page":"42413","DOI":"10.1038\/srep42413","article-title":"Interleukin-33 produced by M2 macrophages and other immune cells contributes to Th2 immune reaction of IgG4-related disease","volume":"7","author":"Furukawa","year":"2017","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.152062_bib0076","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3899\/jrheum.140234","article-title":"The Interleukin 33\/ST2 axis in patients with primary Sjogren syndrome: expression in serum and salivary glands, and the clinical association","volume":"42","author":"Jung","year":"2015","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.152062_bib0077","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1136\/annrheumdis-2012-203187","article-title":"Potential involvement of the IL-33-ST2 axis in the pathogenesis of primary Sjogren's syndrome","volume":"73","author":"Awada","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152062_bib0078","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1124\/jpet.114.222505","article-title":"Targeting IL-33 in autoimmunity and inflammation","volume":"354","author":"Theoharides","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.152062_bib0079","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/emboj.2011.497","article-title":"A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death","volume":"31","author":"Garg","year":"2012","journal-title":"EMBO J"},{"key":"10.1016\/j.semarthrit.2022.152062_bib0080","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3389\/fimmu.2015.00422","article-title":"DAMPs from Cell Death to New Life","volume":"6","author":"Venereau","year":"2015","journal-title":"Front Immunol"},{"issue":"24","key":"10.1016\/j.semarthrit.2022.152062_bib0081","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1056\/NEJMra1205750","article-title":"Purinergic signaling during inflammation","volume":"367","author":"Eltzschig","year":"2012","journal-title":"N Engl J Med"},{"issue":"7500","key":"10.1016\/j.semarthrit.2022.152062_bib0082","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/nature13085","article-title":"Nucleotide signalling during inflammation","volume":"509","author":"Idzko","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.semarthrit.2022.152062_bib0083","first-page":"414","article-title":"ATP release and purinergic signaling in NLRP3 inflammasome activation","volume":"3","author":"Gombault","year":"2012","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.152062_bib0084","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/nri2938","article-title":"Immune cell regulation by autocrine purinergic signalling","volume":"11","author":"Junger","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.semarthrit.2022.152062_bib0085","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3389\/fphar.2020.00222","article-title":"P2 receptors as therapeutic targets in the salivary gland: from physiology to dysfunction","volume":"11","author":"Khalafalla","year":"2020","journal-title":"Front Pharmacol"},{"issue":"7","key":"10.1016\/j.semarthrit.2022.152062_bib0086","doi-asserted-by":"crossref","first-page":"C790","DOI":"10.1152\/ajpcell.00072.2012","article-title":"P2X7 receptor activation induces inflammatory responses in salivary gland epithelium","volume":"303","author":"Woods","year":"2012","journal-title":"Am J Physiol Cell Physiol"},{"issue":"40","key":"10.1016\/j.semarthrit.2022.152062_bib0087","doi-asserted-by":"crossref","first-page":"16626","DOI":"10.1074\/jbc.M117.790741","article-title":"P2X7 receptor antagonism prevents IL-1beta release from salivary epithelial cells and reduces inflammation in a mouse model of autoimmune exocrinopathy","volume":"292","author":"Khalafalla","year":"2017","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.152062_bib0088","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/odi.12823","article-title":"P2Y2 R deletion ameliorates sialadenitis in IL-14alpha-transgenic mice","volume":"24","author":"Woods","year":"2018","journal-title":"Oral Dis"},{"key":"10.1016\/j.semarthrit.2022.152062_bib0089","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.cca.2017.09.019","article-title":"Enhanced expression of NLRP3 inflammasome-related inflammation in peripheral blood mononuclear cells in Sjogren's syndrome","volume":"474","author":"Kim","year":"2017","journal-title":"Clin Chim Acta"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.152062_bib0090","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1111\/joim.12115","article-title":"The P2X7 receptor-inflammasome complex has a role in modulating the inflammatory response in primary Sjogren's syndrome","volume":"274","author":"Baldini","year":"2013","journal-title":"J Intern Med"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152062_bib0091","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.intimp.2015.05.023","article-title":"Paeoniflorin down-regulates ATP-induced inflammatory cytokine production and P2X7R expression on peripheral blood mononuclear cells from patients with primary Sjogren's syndrome","volume":"28","author":"Yu","year":"2015","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.152062_bib0092","first-page":"354","article-title":"The expression of P2X7 receptors on peripheral blood mononuclear cells in patients with primary Sjogren's syndrome and its correlation with anxiety and depression","volume":"32","author":"Xie","year":"2014","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152062_bib0093","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3109\/14397595.2015.1021409","article-title":"High circulating level of interleukin-18 in patients with primary Sjogren's syndrome is associated with disease activity","volume":"26","author":"Chen","year":"2016","journal-title":"Mod Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.152062_bib0094","doi-asserted-by":"crossref","first-page":"R447","DOI":"10.1186\/ar1209","article-title":"Increased circulating levels and salivary gland expression of interleukin-18 in patients with Sjogren's syndrome: relationship with autoantibody production and lymphoid organization of the periductal inflammatory infiltrate","volume":"6","author":"Bombardieri","year":"2004","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.152062_bib0095","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/joim.12631","article-title":"The P2X7 receptor-NLRP3 inflammasome complex predicts the development of non-Hodgkin's lymphoma in Sjogren's syndrome: a prospective, observational, single-centre study","volume":"282","author":"Baldini","year":"2017","journal-title":"J Intern Med"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.152062_bib0096","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1681\/ASN.2010040430","article-title":"Dangers within: DAMP responses to damage and cell death in kidney disease","volume":"22","author":"Rosin","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semarthrit.2022.152062_bib0097","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.matbio.2017.12.002","article-title":"Biglycan, a novel trigger of Th1 and Th17 cell recruitment into the kidney","author":"Nastase","year":"2018","journal-title":"Matrix Biol"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.152062_bib0098","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3109\/10409238.2015.1033511","article-title":"Advances in Toll-like receptor biology: modes of activation by diverse stimuli","volume":"50","author":"Bryant","year":"2015","journal-title":"Crit Rev Biochem Mol Biol"},{"issue":"11","key":"10.1016\/j.semarthrit.2022.152062_bib0099","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.4161\/cc.20316","article-title":"Small leucine-rich proteoglycans orchestrate receptor crosstalk during inflammation","volume":"11","author":"Moreth","year":"2012","journal-title":"Cell Cycle"},{"issue":"12","key":"10.1016\/j.semarthrit.2022.152062_bib0100","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1369\/0022155412456380","article-title":"Biglycan: a multivalent proteoglycan providing structure and signals","volume":"60","author":"Nastase","year":"2012","journal-title":"J Histochem Cytochem"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.152062_bib0101","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1369\/0022155417740880","article-title":"Danger-associated molecular patterns derived from the extracellular matrix provide temporal control of innate immunity","volume":"66","author":"Frevert","year":"2018","journal-title":"J Histochem Cytochem"},{"issue":"199","key":"10.1016\/j.semarthrit.2022.152062_bib0102","doi-asserted-by":"crossref","first-page":"ra75","DOI":"10.1126\/scisignal.2001868","article-title":"Signaling by the matrix proteoglycan decorin controls inflammation and cancer through PDCD4 and MicroRNA-21","volume":"4","author":"Merline","year":"2011","journal-title":"Sci Signal"},{"issue":"36","key":"10.1016\/j.semarthrit.2022.152062_bib0103","doi-asserted-by":"crossref","first-page":"24035","DOI":"10.1074\/jbc.M109.014266","article-title":"Biglycan, a danger signal that activates the NLRP3 inflammasome via toll-like and P2X receptors","volume":"284","author":"Babelova","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.semarthrit.2022.152062_bib0104","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1186\/s13075-015-0902-0","article-title":"Soluble biglycan: a potential mediator of cartilage degradation in osteoarthritis","volume":"17","author":"Barreto","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2022.152062_bib0105","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.3389\/fimmu.2019.02963","article-title":"Activation of Myd88-dependent TLRs mediates local and systemic inflammation in a mouse model of primary Sjogren's syndrome","volume":"10","author":"Kiripolsky","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.semarthrit.2022.152062_bib0106","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.692216","article-title":"Immune-intrinsic Myd88 directs the production of antibodies with specificity for extracellular matrix components in primary Sjogren's syndrome","volume":"12","author":"Kiripolsky","year":"2021","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.152062_bib0107","first-page":"233","article-title":"Aberrant proteolytic digestion of biglycan and decorin by saliva and exocrine gland lysates from the NOD mouse model for autoimmune exocrinopathy","volume":"18","author":"Yamachika","year":"2000","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2022.152062_bib0108","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.cyto.2014.02.009","article-title":"Early events in Sjogren's syndrome pathogenesis: the importance of innate immunity in disease initiation","volume":"67","author":"Kramer","year":"2014","journal-title":"Cytokine"},{"issue":"12","key":"10.1016\/j.semarthrit.2022.152062_bib0109","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1172\/JCI42213","article-title":"The proteoglycan biglycan regulates expression of the B cell chemoattractant CXCL13 and aggravates murine lupus nephritis","volume":"120","author":"Moreth","year":"2010","journal-title":"J Clin Invest"},{"issue":"443","key":"10.1016\/j.semarthrit.2022.152062_bib0110","doi-asserted-by":"crossref","first-page":"ra86","DOI":"10.1126\/scisignal.aaf3596","article-title":"Distinct microenvironmental cues stimulate divergent TLR4-mediated signaling pathways in macrophages","volume":"9","author":"Piccinini","year":"2016","journal-title":"Sci Signal"},{"key":"10.1016\/j.semarthrit.2022.152062_bib0111","first-page":"391","article-title":"The interleukin-1alpha precursor is biologically active and is likely a key alarmin in the IL-1 family of","volume":"4","author":"Kim","year":"2013","journal-title":"Cytokines. Front Immunol"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.152062_bib0112","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102763","article-title":"Interleukin 1alpha: a comprehensive review on the role of IL-1alpha in the pathogenesis and treatment of autoimmune and inflammatory diseases","volume":"20","author":"Cavalli","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2022.152062_bib0113","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1146\/annurev.immunol.021908.132612","article-title":"Immunological and inflammatory functions of the interleukin-1 family","volume":"27","author":"Dinarello","year":"2009","journal-title":"Annu Rev Immunol"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.152062_bib0114","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.smim.2013.10.005","article-title":"Apte Interleukin-1alpha","volume":"25","author":"Rider","year":"2013","journal-title":"Semin Immunol"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152062_bib0115","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/1873-3468.12933","article-title":"How stress contributes to autoimmunity-lessons from Sjogren's syndrome","volume":"592","author":"Skopouli","year":"2018","journal-title":"FEBS Lett"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152062_bib0116","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1600-0714.2012.01181.x","article-title":"Salivary gland hypofunction induced by activation of innate immunity is dependent on type I interferon signaling","volume":"42","author":"Nandula","year":"2013","journal-title":"J Oral Pathol Med"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.152062_bib0117","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0126277","article-title":"Upregulation of NLRP3 inflammasome in the tears and ocular surface of dry eye patients","volume":"10","author":"Niu","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.semarthrit.2022.152062_bib0118","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/978-1-4615-5359-5_75","article-title":"Pflugfelder Alterations of ocular surface gene expression in Sjogren's syndrome","volume":"438","author":"Jones","year":"1998","journal-title":"Adv Exp Med Biol"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.152062_bib0119","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1076\/ceyr.19.3.201.5309","article-title":"Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjogren's syndrome keratoconjunctivitis sicca","volume":"19","author":"Pflugfelder","year":"1999","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.semarthrit.2022.152062_bib0120","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.clim.2017.04.003","article-title":"Innate immunity in Sjogren's syndrome","volume":"182","author":"Kiripolsky","year":"2017","journal-title":"Clin Immunol"},{"key":"10.1016\/j.semarthrit.2022.152062_bib0121","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.exer.2018.03.026","article-title":"Comparative analysis on the dynamic of lacrimal gland damage and regeneration after Interleukin-1alpha or duct ligation induced dry eye disease in mice","volume":"172","author":"Dietrich","year":"2018","journal-title":"Exp Eye Res"},{"issue":"3","key":"10.1016\/j.semarthrit.2022.152062_bib0122","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.2353\/ajpath.2010.100227","article-title":"Interleukin-1 as a phenotypic immunomodulator in keratinizing squamous metaplasia of the ocular surface in Sjogren's syndrome","volume":"177","author":"Chen","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1016\/j.semarthrit.2022.152062_bib0123","first-page":"1957","article-title":"Topical administration of interleukin-1 receptor antagonist as a therapy for aqueous-deficient dry eye in autoimmune disease","volume":"19","author":"Vijmasi","year":"2013","journal-title":"Mol Vis"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.152062_bib0124","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/ICL.0000000000000276","article-title":"Multicenter study of a novel topical interleukin-1 receptor inhibitor, isunakinra, in subjects with moderate to severe dry eye disease","volume":"43","author":"Goldstein","year":"2017","journal-title":"Eye Contact Lens"},{"issue":"6","key":"10.1016\/j.semarthrit.2022.152062_bib0125","doi-asserted-by":"crossref","first-page":"306","DOI":"10.5114\/reum.2016.64907","article-title":"Calprotectin in rheumatic diseases: a review","volume":"54","author":"Kopec-Medrek","year":"2016","journal-title":"Reumatologia"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152062_bib0126","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003848","article-title":"DAMP molecule S100A9 acts as a molecular pattern to enhance inflammation during influenza A virus infection: role of DDX21-TRIF-TLR4-MyD88 pathway","volume":"10","author":"Tsai","year":"2014","journal-title":"PLoS Pathog"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152062_bib0127","first-page":"129","article-title":"Phagocyte-specific S100A8\/A9 is upregulated in primary Sjogren's syndrome and triggers the secretion of pro-inflammatory cytokines in vitro","volume":"35","author":"Nicaise","year":"2017","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"10.1016\/j.semarthrit.2022.152062_bib0128","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/jop.12763","article-title":"Salivary S100A8\/A9 in Sjogren's syndrome accompanied by lymphoma","volume":"47","author":"Jazzar","year":"2018","journal-title":"J Oral Pathol Med"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152062_bib0129","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3109\/03009742.2013.848930","article-title":"Calprotectin (S100A8\/A9), S100A12, and EDTA-resistant S100A12 complexes (ERAC) in primary Sjogren's syndrome","volume":"43","author":"Nordal","year":"2014","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.152062_bib0130","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12014-019-9245-1","article-title":"Phenotyping multiple subsets in Sjogren's syndrome: a salivary proteomic SWATH-MS approach towards precision medicine","volume":"16","author":"Cecchettini","year":"2019","journal-title":"Clin Proteomics"},{"issue":"8","key":"10.1016\/j.semarthrit.2022.152062_bib0131","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1681\/ASN.2011111077","article-title":"Histones from dying renal cells aggravate kidney injury via TLR2 and TLR4","volume":"23","author":"Allam","year":"2012","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.152062_bib0132","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.4049\/jimmunol.1003930","article-title":"Extracellular histones are mediators of death through TLR2 and TLR4 in mouse fatal liver injury","volume":"187","author":"Xu","year":"2011","journal-title":"J Immunol"},{"issue":"12","key":"10.1016\/j.semarthrit.2022.152062_bib0133","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1002\/eji.201243224","article-title":"Histones trigger sterile inflammation by activating the NLRP3 inflammasome","volume":"43","author":"Allam","year":"2013","journal-title":"Eur J Immunol"},{"issue":"5","key":"10.1016\/j.semarthrit.2022.152062_bib0134","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00109-014-1148-z","article-title":"Extracellular histones in tissue injury and inflammation","volume":"92","author":"Allam","year":"2014","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.semarthrit.2022.152062_bib0135","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3389\/fcimb.2020.00196","article-title":"Extracellular histone H3 induces pyroptosis during sepsis and may act through NOD2 and VSIG4\/NLRP3 pathways","volume":"10","author":"Shi","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"issue":"4","key":"10.1016\/j.semarthrit.2022.152062_bib0136","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1021\/acs.jproteome.6b01051","article-title":"Alterations in the salivary proteome and N-glycome of Sjogren's syndrome patients","volume":"16","author":"Hall","year":"2017","journal-title":"J Proteome Res"},{"issue":"8","key":"10.1016\/j.semarthrit.2022.152062_bib0137","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/pmic.201000206","article-title":"Identification of autoantibody biomarkers for primary Sjogren's syndrome using protein microarrays","volume":"11","author":"Hu","year":"2011","journal-title":"Proteomics"},{"key":"10.1016\/j.semarthrit.2022.152062_bib0138","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/978-981-15-3449-2_11","article-title":"Epigenetics in primary Sjogren's syndrome","volume":"1253","author":"Bordron","year":"2020","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"10.1016\/j.semarthrit.2022.152062_bib0139","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1365-2249.2005.02892.x","article-title":"Cross-recognition between histones and La\/SSB may account for anti-DNA reactivity in SLE patients","volume":"142","author":"Touloupi","year":"2005","journal-title":"Clin Exp Immunol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017222001135?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017222001135?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:09:33Z","timestamp":1758733773000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017222001135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":139,"alternative-id":["S0049017222001135"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2022.152062","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunopathogenesis of Sjogren's syndrome: Current state of DAMPs","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2022.152062","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"152062"}}